Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-Resistant Pancreatic Cancer. // Gastroenterology. – URL: https://www.sciencedirect.com/science/article/pii/S0016508526073488?dgcid=rss_sd_all
Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-Resistant Pancreatic Cancer. Gastroenterology. https://www.sciencedirect.com/science/article/pii/S0016508526073488?dgcid=rss_sd_all
“Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-Resistant Pancreatic Cancer.” Gastroenterology.
@article{article118669,
title = {Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-Resistant Pancreatic Cancer},
journal = {Gastroenterology},
url = {https://www.sciencedirect.com/science/article/pii/S0016508526073488?dgcid=rss_sd_all}
}